Arrhythmias & electrophysiology
Stereotactic arrhythmia radioablation and its implications for modern cardiac electrophysiology: results of an EHRA survey
Authors' conclusion
Stereotactic arrhythmia radioablation as a novel treatment option of recurrent VT appears to gain acceptance within the cardiology community.
Study context
- Population
- International cardiologists (EHRA survey) on stereotactic arrhythmia radioablation (STAR) for recurrent VT/VF91 [59.9%] electrophysiologists
- Participants
- 129 cardiologists
- Outcome
- Current role, barriers to application and expected future role of STAR
Methodological detailsonline survey, 20 questions, international
- Online survey
- 20 questions
- International
Main finding
As reported in the abstract
- Unaware of STAR as a therapeutic option
- 9 (7%)
- Access to STAR
- 64 (49.6%)
- Treated/referred a patient for STAR
- 62 (48.1%)
- Primary indication: recurrent VT/VF in structural heart disease (SHD)
- 45%
- Primary indication: recurrent VT/VF without SHD
- 7.8%
- Primary indication: premature ventricular contraction
- 3.9%
- Main advantage: efficacy in arrhythmias not amenable to conventional treatment
- 49%
- Main advantage: non-invasive, low expected acute and short-term procedural risk
- 23%
- Foresee future clinical role in VT/VF with SHD
- 72%
- Foresee future clinical role in VT/VF without SHD
- 75%
- Expect first-line indication, VT/VF with SHD
- 7%
- Expect first-line indication, VT/VF without SHD
- 5%
Observational data: associations, not effects.
Original publication
Stereotactic arrhythmia radioablation and its implications for modern cardiac electrophysiology: results of an EHRA survey. Europace. Published 26 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →